Merck announces positive results from phase 3 KEYNOTE-859 trial of Keytruda plus chemotherapy to treat patients with HER2-negative gastric or GEJ adenocarcinoma
By, Admin1 min read
Share
Merck, known as MSD outside of the United States and Canada, announced results from the pivotal phase 3 KEYNOTE-859 trial investigating Keytruda, Merck
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
